Physician profile
David Van Duin
NPI 1225124621
$67,390.41
in general payments reported to CMS, 2019-2025
9 companies · $1,968 in 2025
The $1,968 reported for 2025 was more than what 85% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,708 · 2020: $3,295 · 2021: $21K · 2022: $7,955 · 2023: $12K · 2024: $13K · 2025: $1,968.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $27K · Food and Beverage: $218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $26,740.00 |
| Food and Beverage | $217.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| F. Hoffmann-La Roche Ag | $30,000.00 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $11,034.75 | 2019-2021 | |
| Genentech, INC. | $10,800.00 | 2021 | |
| Abbvie INC. | $7,769.74 | 2022-2024 | |
| Shionogi INC | $5,270.00 | 2019-2022 | |
| Melinta Therapeutics, LLC | $1,625.00 | 2022 | |
| Roche Products Limited | $640.00 | 2025 | |
| La Jolla Pharmaceutical Company | $128.15 | 2025 | Zevtera, Xerava, Giapreza |
| Allergan, INC. | $122.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Van Duin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.